Condition (MeSH)
Hamartoma Syndrome, Multiple
ClinicalTrials.gov lists 26 trials for Hamartoma Syndrome, Multiple or a narrower condition beneath it. National Human Genome Research Institute (NHGRI) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 26 trials are tagged with Hamartoma Syndrome, Multiple itself; the rest are tagged with a narrower condition beneath it.
When did Hamartoma Syndrome, Multiple trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 3 |
| 2015 | 3 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hamartoma Syndrome, Multiple trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 3 |
| Phase 2 | 3 |
| Phase 2/3 | 1 |
| Not applicable | 4 |
| Observational | 12 |
| Expanded access | 1 |
How many Hamartoma Syndrome, Multiple trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 8 |
| Active, not recruiting | 3 |
| Completed | 10 |
| Withdrawn | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hamartoma Syndrome, Multiple trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Human Genome Research Institute (NHGRI) | 4 |
| National Cancer Institute (NCI) | 2 |
| Novartis Pharmaceuticals | 2 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
Which drugs are being tested for Hamartoma Syndrome, Multiple? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sirolimus | 3 |
| 18F-FDG | 1 |
| BGT226 | 1 |
| EVEROLIMUS | 1 |
| BEZ235 | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| MK-7075 (miransertib) | 2 |
| Influvac Tetra | 1 |
| Everolimus blinded oral capsules | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hamartoma Syndrome, Multiple trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Enterovirus infection | 1 | 1 |
| Renal lesions | 1 | 1 |
| Suicidal ideation | 1 | 1 |
Which publications cover Hamartoma Syndrome, Multiple? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Sirolimus for Colon Polyposis in PTEN Hamartoma Tumor Syndrome. | Clinical and translational gastroenterology | 2025 | Yes |
| A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. | Human molecular genetics | 2022 | Yes |
| A phase II study of TAS-117 in patients with advanced solid tumors harboring germline <i>PTEN</i>-inactivating mutations. | Future oncology (London, England) | 2022 | Yes |
| Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study. | British journal of cancer | 2021 | Yes |
| Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. | Frontiers in endocrinology | 2021 | Yes |
Showing 5 of 20 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Cowden syndrome | Point prevalence | 1-9 / 1 000 000 | Netherlands | Not stated | Exact |
| Cowden syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Cowden syndrome | Point prevalence | 1-9 / 1 000 000 | Netherlands | Not stated | Exact |
| Cowden syndrome | Point prevalence | 1-9 / 1 000 000 | Netherlands | Not stated | Unspecified |
| Cowden syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Cowden syndrome | 201 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Cowden syndrome | 201 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.